Agilent Technologies, Inc. logo
AAgilent Technologies, Inc.

The forward PE ratio is 21.31 as of Thursday, July 9, 2026.

Forward PE Ratio (21.31) = Close Price ($133.59) / Consensus Forward EPS ($6.06)

A Forward PE Ratio Metrics

FORWARD PE RATIO

21.31

A Competitors' Forward PE Ratio

A

Agilent Technologies, Inc.

Current

Market Cap

$37.73B

Forward PE Ratio

21.31

IQV

IQVIA Holdings Inc.

vs A

Market Cap

$34.88B

Forward PE Ratio

15.90

MDLN

Medline Inc.

vs A

Market Cap

$34.54B

Forward PE Ratio

26.62

CNC

Centene Corp.

vs A

Market Cap

$33.38B

Forward PE Ratio

19.16

ZTS

Zoetis Inc.

vs A

Market Cap

$31.48B

Forward PE Ratio

10.91

IDXX

IDEXX Laboratories, Inc.

vs A

Market Cap

$44.06B

Forward PE Ratio

37.91

VEEV

Veeva Systems Inc.

vs A

Market Cap

$30.82B

Forward PE Ratio

23.70

MRNA

Moderna, Inc.

vs A

Market Cap

$30.38B

Forward PE Ratio

N/A

RMD

ResMed Inc.

vs A

Market Cap

$30.24B

Forward PE Ratio

18.53

GEHC

GE HealthCare Technologies Inc.

vs A

Market Cap

$29.43B

Forward PE Ratio

13.25

Trailing vs Forward

Trailing P/E

25.9

reported TTM EPS

Forward P/E

21.3

consensus next-FY EPS

The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $6.06 implies +21.7% EPS growth vs the reported trailing $4.98.

Forward P/E by Fiscal Year

View All Analyst Estimates

At today's $133.59 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.

Fiscal year endConsensus EPSEstimate rangeAnalystsImplied P/E
2026-10-31$6.06$5.96 – $6.121222.1x
2027-10-31$6.60$6.47 – $6.701220.2x
2028-10-31$7.31$6.79 – $7.89618.3x

Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.

Forward PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Forward PE Ratio FAQ

What is the forward PE ratio for Agilent Technologies, Inc. (A)?
The forward PE ratio for A stock is 21.31.

About Agilent Technologies, Inc.

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Santa Clara, CA
17,900 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Padraig McDonnell